Streetbeat News

Partnerships

DVA

The American Diabetes Association (ADA) and DaVita (NYSE:DVA) have expanded their multi-year collaboration to advance chronic disease prevention, focusing on diabetes and chronic kidney disease (CKD). This expansion, announced during National Kidney Month, includes a $1.5 million contribution from DaVita to the ADA's initiatives. The partnership aims to increase awareness, education, and support, especially in communities of color disproportionately affected by these conditions. Efforts include creating educational materials, a dietitian program, and sponsoring ADA's State of Diabetes events.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 8:44 pm

NEXT

NextDecade Corporation (NASDAQ:NEXT) provided a Q4 2023 business update, focusing on the construction of Phase 1 at the Rio Grande LNG Facility and the expansion capacity to meet global LNG demand. The company is working with Bechtel on construction and has begun FEED and EPC contract processes for Train 4, aiming for a positive FID in H2 2024. Financially, NextDecade has secured loans and issued senior secured notes to support Phase 1 construction, with significant progress reported in project completion percentages for Trains 1, 2, and 3.

Portfolio Pulse from Happy Mohamed

March 11, 2024 | 8:36 pm

AAP

Advance Auto Parts has appointed three new independent directors and entered into a cooperation agreement with Third Point and Saddle Point Management. This strategic move aims to enhance governance and drive shareholder value.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 8:20 pm

NPWR

NET Power Inc. (NYSE:NPWR) reported its Q4 and year-end 2023 results, highlighting significant progress in its projects and strategic partnerships. The company ended 2023 with approximately $637M in cash and short-term investments, with no debt. Key developments include advancing the Project Permian in West Texas, signing agreements with Baker Hughes and Lummus Technology, and planning for equipment validation campaigns. NET Power also completed a business combination with Rice Acquisition Corp. II, becoming publicly listed on the NYSE in June 2023.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 8:11 pm

ALTO

Alto Ingredients has announced its intention to collaborate with Vault on a carbon capture and storage initiative. As part of this initiative, Alto will install equipment to capture carbon dioxide generated from its production process at its Pekin campus. Vault will then be responsible for the transportation and storage of these emissions.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 8:04 pm

AAP

Advance Auto Parts (AAP) shares are experiencing an uptick after reports emerged that the company is nearing a settlement with Third Point, which includes the addition of three new board members.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 7:57 pm

ASLN

Piper Sandler released a note on ASLAN Pharmaceuticals, indicating the company's belief in the value and differentiation of its once-monthly subcutaneous Eblasakimab compared to Dupixent, which is administered every other week. This suggests ASLAN Pharmaceuticals is open to partnerships or acquisition based on the unique positioning of Eblasakimab.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 6:45 pm

MRNA

Moderna shares are trading higher following the announcement of a new Phase 2/3 trial of pembrolizumab (Keytruda) by Merck in combination with Moderna's V940 for cutaneous squamous cell carcinoma. The trial's posting on clinicaltrials.gov and Jefferies' positive outlook on the program's investment and confidence have contributed to the optimism.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 6:09 pm

MRK

MRNA

Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) are collaborating on a new clinical trial for V940, an individualized neoantigen therapy, combined with pembrolizumab for treating advanced cutaneous squamous cell carcinoma. The Phase 2 trial will evaluate the safety and efficacy of this combination compared to standard care. The trial is expected to start next month and conclude by 2029. Analysts from Jefferies and RBC Capital have expressed positive views on this development, highlighting the potential of the therapy and the growing incidence of cSCC. MRNA shares rose 8.96% to $112.26.

Portfolio Pulse from Vandana Singh

March 11, 2024 | 6:09 pm

MRNA

Moderna's shares are up due to the announcement of a new Phase 2/3 trial for pembrolizumab (Keytruda) plus Moderna's V940 in cutaneous squamous cell carcinoma, as listed on clinicaltrials.gov. Jefferies' commentary on the trial suggests increased investment and confidence in the program.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 6:07 pm